Core Insights - The company Innovent Biologics has successfully included seven innovative products in the newly released 2025 National Medical Insurance Directory, which includes the PD-1 inhibitor, Tyvyt® (sintilimab injection) and other mature products with expanded indications [1] Group 1: Product Inclusion - The newly added indications for Tyvyt® mean that all eight approved indications are now covered by medical insurance [1] - The directory also includes several recently launched new drugs targeting oncology and chronic diseases, such as China's first approved KRAS G12C inhibitor, Elunate® (fruquintinib), and the IGF-1R antibody drug, IBI310 (tislelizumab) [1] Group 2: Market Position - Currently, Innovent Biologics has a total of 17 innovative drugs on the market, with 12 of them included in the National Medical Insurance Directory [1]
信达生物7款创新药进入新版医保目录